Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
Healthcare
$3.83 -3.37%
-$0.34 today
- Market cap
- $189.33M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
52W Low $1.47High $14.53
Volume 0.77M
Average 0.48M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$76.75M
FY 2025 · Annual
Investing Cash Flow
$63.41M
FY 2025 · Annual
Financing Cash Flow
$9,000.00
FY 2025 · Annual
-100.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.83M) | (58.79M) | (28.72M) | (65.37M) | (83.87M) |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.31M | 6.58M | 7.05M | 6.98M | 6.82M |
| Change in Working Capital | 33.41M | (3.87M) | (28.28M) | (325K) | (424K) |
| Accounts Receivables | (468K) | (57K) | (1.23M) | 1.61M | 79K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.24M) | 190K | (408K) | 519K | (760K) |
| Other Working Capital | 35.13M | (4M) | (26.64M) | (2.46M) | 257K |
| Other Non-Cash Items | 18.55M | 4.08M | 251K | 1.26M | (1.88M) |
| Operating Cash Flow | (15.3M) | (50.83M) | (47.43M) | (55.03M) | (76.75M) |
| Capital Expenditures | (1.72M) | (6.3M) | (3.26M) | (642K) | (2.59M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (49.52M) | (176.17M) | (44.88M) |
| Sales of Investments | 0 | 0 | 26.8M | 56.35M | 110.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.72M) | (6.3M) | (25.98M) | (120.46M) | 63.41M |
| Debt Repayment | 0 | 0 | 0 | (149K) | (132K) |
| Common Stock Issued | 0 | 0 | 0 | 166.51M | 371K |
| Common Stock Repurchased | 0 | (5K) | (12K) | (4.18M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.86M) | (1.26M) | 24.4M | 51K | (230K) |
| Financing Cash Flow | 152.75M | (1.26M) | 24.39M | 162.23M | 9K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 135.73M | (58.39M) | (49.01M) | (13.27M) | (13.33M) |
| Free Cash Flow | (17.03M) | (57.13M) | (50.69M) | (55.67M) | (79.34M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$83.9M
+ D&A$2.6M
+ Stock-Based Comp$6.8M
+ Deferred Tax$0
- Working Capital-$424.0K
- Other Non-Cash-$1.9M
= Operating Cash Flow-$76.8M
- Capex-$2.6M
= Free Cash Flow-$79.3M
Analysis
FY2025 free cash flow is -$79.3M. FCF conversion is 94.6% of net income. Operating cash flow was -$76.8M, with capex of -$2.6M. The largest bridge item is Stock-Based Comp at $6.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K/A | 8-K/A filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
Does ARTV generate free cash flow?
Artiva Biotherapeutics, Inc. (ARTV) generated -$79.34M of free cash flow in fiscal 2025.
How much operating cash flow does ARTV produce?
Operating cash flow was -$76.75M, before capital expenditures of $2.59M.
Continue the stock analysis
Jump to another research area for this company.